<DOC>
	<DOCNO>NCT00065767</DOCNO>
	<brief_summary>The aim study determine effectiveness treatment raloxifene , estrogen-like medication approve Food Drug Administration treatment osteoporosis , improve memory ability live independently postmenopausal woman Alzheimer 's disease .</brief_summary>
	<brief_title>Cognitive Neurophysiological Effects Raloxifene Alzheimer 's Disease</brief_title>
	<detailed_description>The aim study determine effectiveness treatment raloxifene , estrogen-like medication ( classified Selective Estrogen Receptor Modulators ( SER 's ) ) approve Food Drug Administration treatment osteoporosis , improve memory ability live independently postmenopausal woman Alzheimer 's disease . Patients volunteer study need visit clinic 7 time ( participate ) period five month receive either raloxifene harmless , inactive pill call placebo . Neither volunteer study staff know type pill patient receives . Patients must generally healthy mild-to-moderate dementia . There must patient caregiver watch side effect ensure patient take study pill schedule period three month . Patients undergo neuropsychological test evaluation ability live independently visit well laboratory evaluation , take blood . Each visit last approximately 3 hour . A total 20 patient recruit participate study University Wisconsin .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Raloxifene Hydrochloride</mesh_term>
	<criteria>Postmenopausal woman Alzheimer 's disease without dementia ( diagnose study staff outside clinic ) Mini Mental Status Exam score great 15/30 History deep vein thrombosis blot clot Diabetes Active heart disease stroke Liver problem include hepatitis Severe vision hear problem Tobacco use</criteria>
	<gender>Female</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>Alzheimer disease</keyword>
	<keyword>Postmenopausal woman</keyword>
	<keyword>Hormone therapy</keyword>
</DOC>